Dihydropyrimidine dehydrogenase inhibition as a strategy for the oral administration of 5-fluorouracil: Utility in the treatment of advanced colorectal cancer

Anti-Cancer Drugs

Volumn 14, Issue 9, 2003, Pages 695-702

  Schmoll, Hans Joachim ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Colorectal cancer; DIF; Dihydropyrimidine dehydrogenase; Eniluracil; Oral fluoropyrimidine; S 1; Tegafur

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; 5 ETHYNYLURACIL; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; PRODRUG; UFT;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG INDICATION; DRUG METABOLISM; DRUG SAFETY; ENZYME INHIBITION; GASTROINTESTINAL TOXICITY; GRANULOCYTOPENIA; HUMAN; HYPERBILIRUBINEMIA; LEUKOPENIA; MUCOSA INFLAMMATION; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; REVIEW; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0242319843     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200310000-00003     Document Type: Review

References (59)

1. Meta-analysis Group in Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998; 16:301-308.
2. Lokich JJ, Ahlgren JD, Gullo JJ, Philips JA, Fryer JG. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program study. J Clin Oncol 1989; 7:425-432.
3. Fraile RJ, Baker LH, Buroker TR, Horowitz J, Vaitkevicius VK. Pharmacokinetics of 5-fluorouracil administered orally, by rapid intravenous and slow infusion. Cancer Res 1980; 40:2223-2228.
4. Heggie GD, Sommadossi JP, Cross DS, Huster WJ, Diasio RB. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine and bile. Cancer Res 1987; 47:2203-2206.
5. McLeod HJ, Sludden J, Murray GI, Keenan RA, Davidson AI, Park K, et al. Characterisation of dihydropyrimidine dehydrogenase in human colorectal tumours. Br J Cancer 1998; 77:461-465.
6. Baker SD, Diasio RB, O'Reilly S, Lucas VS, Khor SP, Sartorius SE, et al. Phase I and pharmacologic study of oral fluorouracil on a chronic daily schedule in combination with the dihydropyrimidine dehydrogenase inactivator eniluracil. J Clin Oncol 2000; 18:915-926.
7. Naguib FNM, El-Kouni MH, Sha S. Enzymes of uracil catabolism in normal and neoplastic human tissues. Cancer Res 1985; 45:5402-5412.
8. Au JL, Wu AT, Friedman MA, Sadee W. Pharmacokinetics and metabolism of ftorafur in man. Cancer Treat Rep 1979; 63:343-350.
9. Fujii S, Kitano S, Ikenaka K, Shirasaka T. Effect of coadministration of uracil or cytosine on the antitumor activity of clinical dose of 1-(2-tetrahydrofuryl)-5-fluorouracil and level of 5-fluorouracil in rodents. Gann 1979; 70: 209-214.
10. Friedman MA, Ignoffo RJ. A review of the United States clinical experience of the fluoropyrimidine, ftorafur (NSC-1458958). Cancer Treat Rev 1980; 7:205-213.
11. 1-2′-furanidyl-5- fluorouracil). Cancer Res 1976; 36:1821-1824.
12. Bjerkeset T, Fjosne HE. Comparison of oral ftorafur and intravenous 5-fluorouracil in patients with advanced cancer of the stomach, colon or rectum. Oncology 1986; 43:212-215.
13. Palmeri S, Gebbia V, Russo A, Armata MG, Gebbia N, Rausa L. Oral tegafur in the treatment of gastrointestinal tract cancer: a phase II study. Br J Cancer 1990; 61:475-478.
14. Ron IG, Lotan A, Inbar MJ, Chaitchik S. Advanced colorectal carcinoma: redefining the role of oral ftorafur. Anticancer Drugs 1996; 7:649-654.
15. Nogue M, Segui MA, Saigi E, Batiste-Alentorn E, Arcusa A, Boleda M, et al. Protracted treatment with tegafur and low dose oral leucovorin in patients with advanced colorectal carcinoma. Cancer 1998; 83:254-258.
16. Taguchi T, Nakano Y, Jikuya K, Fujii S, Ikenaka K, Fuku-Shima M, et al. Effect of uracil on the antitumor activity of ftorafur. Jpn J Cancer Chemother 1978; 5:1161-1165.
17. Kawaguchi Y, Nagayame S, Masuda H, Yasuda A. Studies on the metabolism of 1-(2′-tetrahydrofuranyl)-5-fluorouracil and uracil coadministered orally to tumor-bearing rats. Gann 1980; 17: 889-899.
18. Pazdur R, Lassere Y, Diaz-Canton E, Bready B, Ho DH. Phase I trials of uracil-tegafur (UFT) using 5 and 28 day administration schedules - demonstration of schedule dependent toxicities. Anticancer Drugs 1996; 7:728-733.
19. Muggia FM, Wu XY, Spicer D, Groshen S, Jeffers S, Leichman CG, et al. A phase I and pharmacokinetic study of oral UFT a combination of the 5-fluorouracil prodrug tegafur and uracil. Clin Cancer Res 1996; 2:1461-1467.
20. 1-(2′- tetrahydrofuryl)-5-fluorouracil. Clin Cancer Res 1998; 4:2085-2088.
21. Rustum YM. Mechanism-based improvement in the therapeutic selectivity of 5-FU prodrug alone and under conditions of metabolic modulation. Oncology 1997; 54(suppl 1):7-11.
22. Damle B, Ravandi F, Kaul S, Sonnichsen D, Ferreira I, Brooks D, et al. Effect of food on the oral bioavailability of UFT and leucovorin in cancer patients. Clin Cancer Res 2001; 7:517-523.
23. Pazdur R, Lassere Y, Rhodes V, Ajani JA, Sugaman SM, Patt YZ, et al. Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma. J Clin Oncol 1994; 12:2296-2300.
24. Thomas MB, Langlaben A, Rinaldi D, Anthony L, Irwin D, Lassere Y, et al. A phase II study of UFT plus leucovorin given as a twice-daily (BID) regimen in the treatment of patients (Pts) with metastatic colorectal cancer (MCC). Proc Am Soc Clin Oncol 2001; 20:142a (abstr 564).
25. Douillard J-Y, Hoff PM, Skillings JR, Eisenberg P, Davidson N, Harper P, et al. Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2002; 20:3605-3616.
26. Carmichael J, Popiela T, Radstone D, Falk S, Borner M, Oza A, et al. Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2002; 20:3617-3627.
27. NDA Pipeline 1999; 18:V-95-V-100.
28. Benner S. 63rd US Federal Drug Administration Oncology Advisory Board Meeting Slides. Available from URL: http:www.fda.gov/ohrms/dockets/ac/99/slides/ 3540/3540s1d/index.htm.
29. Cunningham D, James RD. Integrating the oral fluoropyrimidines into the management of advanced colorectal cancer. Eur J Cancer 2001; 37:826-834.
30. Twelves CJ, Cassidy J. Which endpoints should we use in evaluating the use of novel fluoropyrimidines regimens in colorectal cancer? Br J Cancer 2002; 86:1670-1676.
31. Smith IE. Epirubicin, cyclophosphamide, and UFT plus oral calcium folinate in advanced breast cancer. Oncology (Huntingt) 1999; 3(7 suppl 3):82-85.
32. Porter DJT, Chestnut WG, Merill BM, Spector T. Mechanism-based inactivation of dihydropyrimidine dehydrogenase by 5-ethynyluracil. J Biol Chem 1992; 267:5236-5242.
33. Baccanari DP, Davis ST, Knick VC, Spector T. 776C85: effects on the pharmacokinetics and antitumour activity of 5-fluorouracil. Proc Natl Acad Sci 1993; 90:11064-11068.
34. Okuda H, Ogura K, Kato A, Takubo H, Watabe T. A possible mechanism of eighteen patient deaths caused by interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs. J Pharmacol Exp Ther 1998; 287:791-799.
35. Yan J, Tyring SK, McCrary MM, Lee PC, Haworth S, Raymond R, et al. The effect of sorivudine on dihydropyrimidine dehydrogenase activity in patients with acute herpes zoster. Clinical Pharmacol Ther 1997; 61:563-573.
36. Schilsky RL, Bukowski R, Burris III H, Hochster H, O'Rourke M, Wall JG, et al. A multicenter phase II study of a five-day regimen of oral 5-fluorouracil plus eniluracil with or without leucovorin in patients with metastatic colorectal cancer. Ann Oncol 2000; 11:415-420.
37. Mani S, Hochster H, Beck T, Chevlen EM, O'Rourke MA, Weaver CH, et al. Multicenter phase II study to evaluate a 28-day regimen of oral fluorouracil plus eniluracil in the treatment of patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2000; 18:2894-2901.
38. Van Cutsem E, Sorensen J, Cassidy J, Daniel F, Harper P, Bailey N, et al. International phase III study of oral eniluracil (EU) plus 5-fluorouracil (5-FU) versus intravenous (IV) 5-FU plus leucovorin (LV) in the treatment of advanced colorectal cancer (ACC). Proc Am Soc Clin Oncol 2001; 20:131a (abstr 522).
39. Schilsky RL, Levin J, West WH, Wong A, Colwell B, Thirlwell MP, et al. Randomized, open-label, phase III study of a 28-day oral regimen of eniluracil plus fluorouracil versus intravenous fluorouracil plus leucovorin as first-line therapy in patients with metastatic/advanced colorectal cancer. J Clin Oncol 2002; 20:1519-1526.
40. van Groeningen CJ, Peters GJ, Schornagel JH, Gall H, Noordhuis P, de Vries MJ, et al. Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors. J Clin Oncol 2000; 18:2772-2779.
41. Ohtsu A, Baba H, Sakata Y, Mitachi Y, Horikoshi N, Sugimachi K, et al. Phase II study of S-1, a novel oral fluoropyrimidine derivative, in patients with metastatic colorectal carcinoma. Br J Cancer 2000; 83:141-145.
42. Van den Brande J, Schöffski P, Schellens J, Roth AD, Duffaud F, Weigang-Kohler K, et al. EORTC Early Clinical Studies Group early phase II trial of S-1 in patients with advanced or metastatic colorectal cancer. Br J Cancer 2003; 88:648-653.
43. Garcia-Girón C, Feliu J, Vincent JM, Madronal C, Fonseca E, Constela M, et al. Phase II trial of oxaliplatin-UFT-leucovorin (OXA-UFT-LV) combination in first line treatment of advanced colorectal cancer (ACC). Proc Am Soc Clin Oncol 2000; 19:293a (abstr 1148).
44. Cruz J, Méndez M, Alfonso PG, Gonzalez E, Pujol E, Castañon C, et al. A phase II study of weekly irinotecan (CPT-11) and oral uracil and ftorafur (UFT) plus folinic acid (FA) as first line treatment in advanced colorectal cancer (CRC). Eur J Cancer 2001; 37(suppl 6):S295 (abstr 1090).
45. Alonso V, Escudero P, Zorrilla M, Isla MD, Herrero A, Mayordomo JI, et al. Phase I trial of weekly irinotecan combined with UFT as second-line treatment for advanced colorectal cancer. Eur J Cancer 2001; 37: 2385-2391.
46. Yip D, Karapetis C, Strickland A, Steer C, Holford C, Harper P. A phase I trial of escalating dose eniluracil/oral 5-fluorouracil plus oxaliplatin (Oxa) in patients with advanced gastrointestinal malignancies. Proc Am Soc Clin Oncol 2001; 20:82b (abstr 2079).
47. Speyer JL, Hochster H, Chachoua A, Farrell K, Cosmidis A, Muggia F. A phase I/II study of eniluracil/5-FU plus oxaliplatin (FOX-E) in patients with pre-treated colorectal cancer. Proc Am Soc Clin Oncol 2001; 20:144a (abstr 574).
48. Borner M, Schöffski P, de Wit R, Caponigro F, Comella G, Sulkes A, et al. Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. Eur J Cancer 2002; 38:349-358.
49. Liu G, Franssen E, Fitch MI, Warner E. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997; 15:110-115.
50. Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998; 34:1274-1281.
51. Hoff PM, Ansari R, Batist G, Cox J, Kocha W, Kuperminc M, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 2001; 19:2282-2292.
52. VanCutsem E, Twelves C, Cassidy J, Allman D, Bajetta E, Boyer M, et al. Oral capecitabine compared with intravenous 5-fluorouracil plus leucovorin (Mayo Clinic regimen) in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001; 19:4097-4106.
53. Twelves C. Capecitabine as first-line treatment in colorectal cancer: pooled data from two large, phase III trials. Eur J Cancer 2002; 38(suppl 2):S15-S20.
54. Dunst J, Reese T, Sutter T, Zuhlke H, Hinke A, Kolling-Schlebusch K, et al. Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer. J Clin Oncol 2002; 20:3983-3991.
55. Schleucher N, Tewes M, Achterrath W, Cao S, Frings S, Wilke H, et al. Extended phase I study of capecitabine and weekly irinotecan as first-line chemotherapy in metastatic colorectal cancer. Eur J Cancer 2001; 37(suppl 6):S290 (abstr 1073).
56. Kerr DJ, Ten Bokkel Huinink WW, Ferry DR, Rea DW, Boussard BM, Oulid-Aissa D, et al. A phase I/II study of CPT-11 in combination with capecitabine as first-line chemotherapy for metastatic colorectal cancer (MCRC). Proc Am Soc Clin Oncol 2002; 21:161a (abstr 643).
57. Diaz-Rubio E, Evans TRJ, Tabernero J, Cassidy J, Sastre J, Eatock M, et al. Capecitabine (Xeloda®) in combination with oxaliplatin: a phase I, dose-escalation study in patients with advanced or metastatic solid tumors. Ann Oncol 2002; 13:558-565.
58. Tabernero J, Butts CA, Cassidy J, Conroy T, de Braud F, Diaz-Rubio E, et al. Capecitabine and oxaliplatin in combination (Xelox) as first line therapy for patients (pts) with metastatic colorectal cancer (MCRC): results of an international multicenter phase II trial. Proc Am Soc Clin Oncol 2002; 21:133a (abstr 531).
59. Levin J, Schilsky R, Burris H, Wong A, Colwell B, Thirlwell M, et al. North American phase III study of oral eniluracil (EU) plus oral 5-fluorouracil (5-FU) versus intravenous (IV) 5-FU plus leucovorin (LV) in the treatment of advanced colorectal cancer (ACC). Proc Am Soc Clin Oncol 2001; 20:132a (abstr 523).